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The chromosome 8p11-p12 amplicon is present in 12% to 15% of breast cancers, resulting in an increase in copy
number and expression of several chromatin modifiers in these tumors, including KAT6A. Previous analyses in
SUM-52 breast cancer cells showed amplification and overexpression of KAT6A, and subsequent RNAi screening
identified KAT6A as a potential driving oncogene. KAT6A is a histone acetyltransferase previously identified as a
fusion partner with CREB binding protein in acute myeloid leukemia. Knockdown of KAT6A in SUM-52 cells, a
luminal breast cancer cell line harboring the amplicon, resulted in reduced growth rate compared to non-silencing
controls and profound loss of clonogenic capacity both in mono-layer and in soft agar. The normal cell line
MCF10A, however, did not exhibit slower growth with knockdown of KAT6A. SUM-52 cells with KAT6A
knockdown formed fewer mammospheres in culture compared to controls, suggesting a possible role for KAT6A
in self-renewal. Previous data from our laboratory identified FGFR2 as a driving oncogene in SUM-52 cells. The
colony forming efficiency of SUM-52 KAT6A knockdown cells in the presence of FGFR inhibition was significantly
reduced compared to cells with KAT6A knockdown only. These data suggest that KAT6A may be a novel
oncogene in breast cancers bearing the 8p11-p12 amplicon. While there are other putative oncogenes in the
amplicon, the identification of KAT6A as a driving oncogene suggests that chromatin-modifying enzymes are a key
class of oncogenes in these cancers, and play an important role in the selection of this amplicon in luminal B
breast cancers.
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A significant step in breast cancer progression is activation of oncogenes
via gene amplification and overexpression [1]. The chromosome
8p11-p12 amplicon, containing approximately 55 genes, is present in
12% to 15% of breast cancers and is correlated with poor prognosis in
primary breast tumors. Amplification of 8p11-p12 is also correlated
with histologic grade, increased Ki-67 proliferation index, and decreased
5-year metastasis-free survival [2–7]. Due to its relevance in breast
cancer, many studies have been aimed at characterizing this
amplification and identifying the driving oncogenes in this region.
Over the past several years, our laboratory and several others have
analyzed the 8p11-p12 amplicon to identify possible driver oncogenes
and determine the clinical relevance of these gene amplification events
in breast cancer. These studies have resulted in the identification of anumber of genes that play a role in breast cancer when the amplicon is
present, including LSM-1, C8orf4 (TC-1), RAB11FIP1, WHSC1L1,
ERLIN2, PROSC, PPAPDC, DDHD2 and others [2,6,8–13].
Gelsi-Boyer et al. demonstrated that the amplicon can be sub-divided
into four distinct regions that can be amplified independently of each
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identified to date from this region [3].
Recently, our lab has taken a genome-scale shRNA screening
strategy to identify additional driving oncogenes in a panel of SUM
breast cancer cell lines, with and without 8p11-p12 amplification, for
which copy number and expression data are available. KAT6A was
found to be a consistent hit in the shRNA screen and is significantly
amplified and overexpressed in SUM-52 cells.
KAT6A, a gene commonly found in the 8p11-p12 amplicon, was
first identified in 1996 as part of a chromosomal translocation
t(8;16)(p11;p13) with CREB-binding protein in a subtype of acute
myeloid leukemia (AML) [14]. Since then, additional translocations
involving KAT6A in AML have been discovered, including
translocations with the HATs p300 and TIF2 [15]. The KAT6A-
TIF2 fusion is capable of immortalizing myeloid progenitor cells and
inducing acute myeloid leukemia upon injection into irradiated mice
[16]. Characterization of KAT6A in these gene rearrangements
provides compelling evidence that KAT6A is an oncogene in
leukemogenesis, much like c-myc, which is well documented in
various chromosomal translocations promoting several forms of
leukemia, and is also amplified in breast cancer.
In this study, we provide evidence that KAT6A functions as a novel
oncogene in luminal breast cancers bearing the 8p11-p12 amplicon. We
identifiedKAT6A as a top shRNA screen hit among genes both amplified
and overexpressed in the SUM-52 breast cancer cell line. The influence of
KAT6A knockdown on proliferation and viability of SUM-52 cells, and
other cell lines with the 8p11-p12 amplicon was validated in separate
experiments involving several short hairpin RNAs (shRNAs). Finally,
data obtained with primary human breast cancers coupled with TCGA
data support a role for KAT6A as a breast cancer oncogene.
Materials and Methods
Reagents
All chemicals were purchased from Sigma Aldrich unless otherwise
noted. Antibodies against Actin and anti-acetyl Histone 3 were
purchased from Millipore. The total-Histone 3 antibody was
purchased from Abcam, and the KAT6A antibody from Novus
Biologicals. The FGFR inhibitor PD170374 was purchased from
Selleckchem. Expression Arrest GIPZ lentiviral KAT6A shRNA
constructs and packaging mix were purchased fromOpen Biosystems.
Primers used for RT-PCR reactions were ordered from IDT. The
SUM breast cancer cell lines were maintained in Hams F-12 cell
culture medium as described previously [17–19].
Cellecta Screening Method
Virus pools expressing shRNA constructs were prepared according to
the Cellecta Pooled Lentiviral shRNA Libraries User Manual protocol
(www.cellecta.com). HEK 293 T cells were transfected with each of the
three Cellecta library plasmid DNA pools (Human Modules 1–3) and
the Cellecta Ready-to-Use PackagingMix (Cat #CPCP-K2A). For each
module, virus was titered and used to transduce 5 × 107 SUM-52 cells at
an MOI of 0.5 in the presence of 5 μg/ml polybrene. Following
transduction, cells were cultured for 3 days to allow expression of the
resistance marker. Non-transduced cells were eliminated from the
culture by the addition of 2 μg/ml puromycin to the growth media.
Three days after the addition of puromycin, cells were trypsinized and
one-half of the total population was harvested for genomic DNA
preparation. This DNA served as the reference time point DNA. Theremaining cells were plated and grown for approximately 7 population
doublings before being harvested for genomic DNA preparation.
Genomic DNA was prepared by phenol:chloroform extraction
according to the Cellecta Pooled Lentiviral shRNA Libraries User
Manual protocol.
See Supplementary Methods for detailed descriptions of the
shRNA screen and statistical analyses.
RT-PCR
For RT-PCR reactions, total RNA was isolated using the Qiagen
RNeasy Plus Mini Kit. RNA was converted into cDNA using the
iScript Advanced cDNA Synthesis Kit (BioRad). Following cDNA
conversion, RT-PCR reactions were performed in 96-well white-
walled plates using FastStart Universal SYBR Green Master mix
(Roche). Reactions were performed on an Eppendorf Mastercycler
Realplex2 under the following parameters: 1 cycle for 10 minutes at
95°C, 1 cycle for 15 seconds at 95°C, and 40 cycles at 53°C for
30 seconds. Primer sets included a control GAPDH primer set and a
primer set specific to the KAT6A transcript.
Growth and Colony-Forming Assays
For growth assays, cells were plated in triplicate in 6-well plates at a
density of 35,000 cells/well. Nuclei were harvested and cell counts
obtained using a Beckman Coulter Counter as described previously [7].
For colony-forming assays, cells were plated in triplicate in 6-well
plates at varying cell densities. Colonies formed for two weeks and
then were fixed with 1 mL/well of 3.7% paraformaldehyde for
20 minutes at RT. Colonies were stained with 1 mL/well of 0.2%
crystal violet for 15 minutes at RT and then de-stained with dH2O.
For colony-forming assays including treatment with the FGFR
inhibitor PD170374, cells were plated as stated above and treated
with 0.1 μM of drug for 3 consecutive days. Colonies formed for an
additional 10–14 days following drug treatment and were stained
with crystal violet as described. Colony counts were generated using
the GelCount System from Oxford Optronix.
Mammosphere Formation
Cells were plated in triplicate for primary mammosphere formation
in low-attachment 6-well plates. Spheres formed for one week, at
which point two wells were transferred to standard 6-well plates in
media supplemented with FBS. Attached spheres were fixed with
1 mL/well of 3.7% paraformaldehyde for 20 minutes at RT and
stained with 1 mL/well of 0.2% crystal violet for 15 minutes at RT.
For secondary mammosphere formation, spheres from one well of the
primary mammosphere assay were harvested and centrifuged at 2500
RPM for 5 minutes. Spheres were re-suspended in 1 mL of trypsin
and incubated at RT for 5 minutes. The trypsin was diluted with
media and centrifuged as before. The cell pellet was washed with
5 mL of PBS and centrifuged, and the final cell pellet was re-
suspended in 1 mL of 1× Hanks buffer solution. Cells were re-plated
in triplicate in 6-well low attachment plates. Spheres were allowed to
form for 2 weeks and then transferred and stained with 0.2% crystal
violet as described above. Images of primary and secondary spheres
were taken using an EVOS Imaging System (Life Technologies).
Mammosphere counts for both primary and secondary assays were
generated using the GelCount System from Oxford Optronix.
RNA Sequencing
Total RNA was prepared using a Qiagen RNeasy Plus Mini Kit
and processed by the MUSC Genomics core for 101-bp, paired-end
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verified on an Agilent 2100 TapeStation (Agilent Technologies, Palo
Alto, CA). 100–200 ng of total RNA was used to prepare RNA-Seq
libraries using the TruSeq RNA Sample Prep kit following the
protocol described by the manufacturer (Illumina, San Diego, CA).
Sequencing was performed on an Illumina HiScanSQ. Samples were
demultiplexed using CASAVA (Illumina, San Diego, CA). Fastq files
were used to map reads to the human genome (hg19, UCSC) utilizing
Tophat2 with default settings. Bam files were imported into Partek
Genomics Suite (St. Louis, MO) for analysis. Samples were filtered for
≥10 reads. Differential gene expression was performed by comparison
of biological duplicate samples in Genomics Suite using advanced
analysis of variance (ANOVA). Differential gene express values were
then filtered by ± 1.5 fold change and by unadjusted P ≤ .05.
Results
Rationale for Studying the Oncogenic Potential of KAT6A
In an effort to comprehensively identify genes that control cell
proliferation and survival in breast cancer cells, our laboratory is
performing genome-scale, RNAi-based negative selection screens in
our panel of SUM breast cancer cell lines. In this screen, the SUM-52
breast cancer cell line was transduced with a library of 82,000 lentiviral
vectors that express shRNAs targeting 15,377 cellular genes with a
minimum of 4 shRNAs per gene. Cells transduced with this library
were harvested at either day 3 after infection or after approximately 7
population doublings, and the abundance of shRNAs at both time
points was determined by PCR amplification, purification and
sequencing of shRNA-associated barcode sequences. Fold depletion
values were calculated by comparing the abundance of each shRNA at
the final time point with the abundance at the initial time point. Fold
depletion scores following statistical analysis for all of the shRNAs
targeting each gene were used to identify genes that are necessary for
the growth/survival of the SUM-52 breast cancer cell line. Integration
of this list with the list of genes that are significantly copy number
amplified in this cell line identified a small number of genes that are
amplified, overexpressed and necessary for growth/survival of the cell
line. KAT6A was found to be a consistent hit in this screen, as well as
an additional screen using an early generation lower complexity
library, and is significantly amplified and overexpressed in SUM-52
cells (Figure 1A).
Based on the RNAi screen data, we performed microarray analysis
to examine the expression level of KAT6A in a small panel of primary
breast cancers available in our lab that potentially carry the 8p11-p12
amplicon. As seen in Figure 1B, several primary tumor samples from
this panel exhibited high levels of KAT6A gene expression.
Additionally, tumors with the highest expression of KAT6A also
had a KAT6A gene amplification. Likewise, a series of SUM breast
cancer cell lines were analyzed by microarray, and KAT6A expression
was highest in cells harboring the 8p11-p12 amplicon, particularly
SUM-52 cells (Figure 1C). The SUM-52 cell line was generated from
a patient with luminal B breast cancer who presented with an
ER-positive primary tumor. The data in Figure 1D shows that
KAT6A protein expression was highest in SUM-52 cells compared to
normal MCF10A cells, SUM-149 and SUM-225 cell lines. Whereas
SUM-225 cells have two small regions of 8p11 amplification, KAT6A
is not amplified in these cells, and SUM-149 cells do not harbor the
8p11-p12 amplicon. As expected, KAT6A protein expression in
SUM-225 cells was barely detectable; however, SUM-149 cells,although lacking the 8p11-p12 amplicon, express KAT6A protein at
levels similar to SUM-52 cells. Because KAT6A is known as a histone
acetyltransferase (HAT) with HAT activity on histone 3, we
examined the acetylation status of histone 3 in cells with amplification
of KAT6A. Total histone 3 acetylation was highest in SUM-52 cells
compared to MCF10A, SUM-225, and SUM-149 cells (Figure 1D);
however, the difference in histone 3 acetylation was most interesting
between SUM-52 and SUM-149 cells. Although both cell lines express
comparable levels of KAT6A protein, histone 3 acetylation was only
increased in SUM-52 cells.
To explore further the relevance of KAT6A in breast cancer, we
examined TCGA data derived from 1,000 primary breast cancers, and
found that KAT6A expression is altered in 22% of breast cancer cases.
Additionally, there is a strong correlation between copy number and
expression at the mRNA level (Figure 1E). Kaplan-Meier analysis of
more than 4000 breast cancer patients (http://kmplot.com/analysis/)
showed that high level KAT6A expression (highest quartile) was
associated with a statistically significant reduction in overall survival
(Figure 1F). Interestingly, the Kaplan-Meier curves diverge after
approximately 100 months of follow-up, suggesting that KAT6A
plays a role in late recurrences, an important clinical problem in
luminal breast cancer. These data support the hypothesis that KAT6A
functions as a driving oncogene in breast cancer, and warrant further
investigation to validate its activity as a transforming oncogene.
KAT6A Knockdown Reduces Growth in 8p11-p12 Amplicon-
Bearing Breast Cancer Cells
To validate the shRNA screen results, KAT6A knockdown studies
were performed with several cell lines. Lentiviral shRNA vectors were
prepared by transfection of 293FT cells with five shRNA plasmids
targeting different KAT6A sequences. Initially, only SUM-52 and
MCF10A cells were transduced with the lentiviral shRNAs.
Following lentiviral infection and puromycin selection, RNA was
harvested to confirm knockdown of KAT6A by RT-PCR. The results
showed that two shRNAs yielded the best knockdown, sh1-566 (sh1)
and sh3-895 (sh3), compared to a non-silencing shRNA sequence,
(NS) (Supplementary Figure 1). To measure the effects of reduced
KAT6A expression on the growth of the SUM-52 and SUM-225 cell
lines, the cells were plated in monolayer in 6-well plates, and their
growth was assessed by cell counts on days 1, 4, and 7. Knockdown of
KAT6A at the message and protein level in SUM-52 cells (Figure 2A)
resulted in 50% reduction in cell growth (Figure 2C). KAT6A is not
part of the 8p11-p12 amplicon in SUM-225 cells, and only a limited
growth response to reduced KAT6A expression was observed
(Figure 2D). Infection of SUM-149 cells, which lack the 8p11-p12
amplicon but still express the protein, did not affect proliferation
(Figure 2E). Additionally, knockdown of KAT6A in MCF10A cells
(Figure 2B) showed no effect on proliferation (Figure 2F). These data
suggest that the effects of KAT6A on breast cancer cell proliferation
are restricted to cells in which the gene is amplified and overexpressed.
KAT6A Reduces the Clonogenic Capacity of SUM-52 Cells
Since reduction of KAT6A expression yielded growth inhibition in
SUM-52 cells, we next addressed the colony-forming efficiency of
SUM-52 cells after knockdown of KAT6A. As shown in Figure 3A,
SUM-52 cells with depleted KAT6A levels exhibited a dramatic
reduction in colony-forming ability compared to control cells.
Moreover, colonies that did grow after KAT6A knockdown were
not only smaller in size, but exhibited an abnormal morphology
Figure 1. Rationale for studying the oncogenic potential of KAT6A. A. Fold depletion scores from the genome-wide shRNA screen were
used to generate probability density plots. The black plot was generated using depletion scores for all genes, the blue plot was generated
using depletion scores for commonly essential genes, the turquoise plot was generated using depletion scores for the negative control
gene set, and the green plot is a normal distribution whosemean was determined by themedian of the fold depletion scores for all genes.
The vertical red line indicates the 95th percentile of the normal distribution that was used as a cutoff for determining hits in the screen.
Black arrows indicate gene scores for Luciferase, KAT6A and FGFR2. B. Microarray data showing relative KAT6A expression in a panel of
primary breast tumors suspected to harbor the 8p11-p12 amplicon. Primary tumors with the highest KAT6A expression were also positive
for possessing the amplicon, as denoted by the asterisk. C. Microarray data showing that relative KAT6A expression is highest in
8p11-p12 amplicon bearing SUM breast cancer cell lines. D.Western blot for KAT6A protein expression in a panel of SUM breast cancer
cell lines. Total Histone 3 acetylation levels were highest in SUM-52 cells, an 8p11-p12 amplicon bearing cell line. E. TCGA data showing
a correlation between KAT6A copy number and mRNA expression. F. Kaplan-Meier analysis with overall survival in over 4,000 breast
cancer cases showing a statistically significant difference in survival in patients with KAT6A amplification/overexpression, with curves
diverging after approximately five years of follow-up.
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scattered colonies composed of cells showing morphological signs of
pyknosis. By contrast, non-silencing control cells produced tightly-
packed colonies with cells displaying a normal appearance. Figure 3Cshows the size distribution of colonies derived from KAT6A
knockdown cells. The largest colonies from the knockdown cells
were approximately 300 μm in diameter, whereas colonies from
control cells were greater than 1000 μm in diameter. The
Figure 2. KAT6A knockdown reduces cell growth in 8p11-p12 amplicon bearing cell lines. A. RT-PCR results showing knockdown of
KAT6A at the mRNA level in SUM-52 and SUM-225 cells transduced with lentivirus using shRNA1 and shRNA3. Below is a corresponding
western blot showing knockdown of KAT6A at the protein level. B. RT-PCR data showing knockdown of KAT6A at the mRNA level in
MCF10A and SUM-149 cells using lentiviral vectors shRNA1 and shRNA3. Below is a corresponding western blot showing knockdown of
KAT6A protein. C - F. SUM-52, SUM-225, MCF10A, and SUM-149 control and KAT6A knockdown cells, respectively, were plated in
triplicate and assayed for growth. Cell counts were taken on days 1, 4 and 7.
648 KAT6A is a Candidate Oncogene in Luminal Breast Cancer Turner-Ivey et al. Neoplasia Vol. 16, No. 8, 2014colony-forming efficiency of MCF10A cells, however, was unaffected
by knockdown of KAT6A (Figure 3D and E). In a separate experiment,
we examined the role of KAT6A knockdown in anchorage-
independent colony formation. KAT6A knockdown also inhibited
the soft agar colony-forming ability of SUM-52 cells, as KAT6A
knockdown cells formed fewer colonies compared to the non-
silencing control (Supplementary Figure 2A and B). To extend theseobservations to other 8p11-p12 harboring cancer cell lines in which
KAT6A is amplified and overexpressed, the ovarian cancer cell lines
OAW28 and 59 M were assayed for colony-forming efficiency
following KAT6A knockdown (Supplementary Figure 3A and B).
These additional cell lines were identified using the TCGA Bioportal
and the Broad Institute’s Cancer Cell Line Encyclopedia, which
indicated a GISTIC copy number score of 1.563 for 59 M cells and
Figure 3. KAT6A reduces the clonogenic capacity of SUM-52 cells. A. SUM-52 control and KAT6A knockdown cells were plated in a
colony-forming assay in triplicate in 6-well low-attachment plates. Colonies were allowed to grow for 2 weeks before staining with
0.2% crystal violet. Adjacent picture depicts the crystal violet-stained colonies. B. Images of SUM-52 control and KAT6A knockdown
colonies taken using an EVOS Imaging System. C. Histogram showing colony size distribution for SUM-52 control and KAT6A
knockdown colonies. D. MCF10A control and KAT6A knockdown cells were plated as above to assay colony-forming efficiency.
Adjacent picture depicts 6-well plates with crystal violet-stained colonies. E. Histogram showing colony size distribution for MCF10A
control and KAT6A knockdown colonies. F and G. OAW28 and 59 M control and KAT6A knockdown cells, respectively, were plated as
stated above for colony forming assay. OAW28 and 59 M are ovarian cancer cell lines positive for both the 8p11-p12 amplicon and
KAT6A amplification.
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and 59 M cells, respectively, responded dramatically to knockdown
of KAT6A, with both cell lines displaying a reduction in colony
forming ability. Based on these results, KAT6A functions in regulating
the clonogenic capacity of not only SUM-52 cells, but also of
other cancer cell lines with the 8p11-p12 amplicon and KAT6A
amplification/overexpression.
KAT6A Plays a Role in Breast Cancer Stem Cell Activity
and Differentiation
In light of the effects of KAT6A knockdown on the growth and
colony-forming efficiency of SUM-52 cells, the role of KAT6A in
breast cancer stem cell activity and self-renewal was examined in a
primary mammosphere assay. As shown in Figure 4A, approximately
2% of non-silencing control SUM-52 cells formed mammospheres.
By contrast, less than 1% of KAT6A knockdown cells formed spheres.
To confirm and extend these results, a secondary mammosphere
assay was performed. The non-silencing control cells formed 4-fold
more mammospheres than in the primary assay, suggesting that the
cells plated for secondary mammosphere assay contained a higher
percentage of cancer-initiating stem cells. Consistent with results in
the primary mammosphere assay, non-silencing control cells again
formed more mammospheres than KAT6A knockdown cells in the
secondary mammosphere assay (Figure 4B). Images of mammo-
spheres revealed striking differences not only between non-silencing
and KAT6A knockdown spheres, but also between primary andFigure 4. KAT6A plays a role in breast cancer stem cell activity. A. SUM
6-well low-attachment plates for a primary mammosphere assay. Aft
plates overnight, stained with 0.2% crystal violet and counted. B
trypsinized, and re-seeded in a secondary mammosphere assay at 3,0
staining. C. Images of primary mammospheres following one week
weeks of growth.secondary mammosphere assays. Mammospheres derived from
control cells displayed classical sphere morphology. Although
KAT6A knockdown spheres appeared similar, they were smaller in
size compared to the control spheres (Figure 4C). Allowing secondary
mammosphere cultures to grow over an extended period revealed a
remarkable difference in morphology between the non-silencing and
KAT6A knockdown mammospheres. Mammospheres derived from
non-silencing control cells began to form three-dimensional duct-like
structures after two weeks in culture (Figure 4D), which were never
observed in mammosphere cultures derived from KAT6A knock-
down cells. These results indicate that SUM-52 cells can form
complex three dimensional structures after extended mammosphere
culture, and that this capacity is lost upon KAT6A knockdown.
In many breast cancer cell types, expression of surface markers is a
measure of stemness and self-renewal potential. In particular, the
CD44+/CD24-/low expression pattern is associated with the breast
cancer stem cell phenotype in some cell lines and tumors. Because
knockdown of KAT6A resulted in reduced mammosphere formation,
we investigated the expression levels of CD24 and CD44 in KAT6A
knockdown and control cells by flow cytometry. Knockdown of
KAT6A resulted in an increase in cells positive for both CD24 and
CD44 to a level approximately three times above the non-silencing
control. Perhaps more interesting was the increase in CD44
expression seen in KAT6A knockdown cells, as evidence now
suggests that CD44 positivity is associated with differentiation [20].
Only 3.1% of non-silencing control cells were positive for CD44,-52 control and KAT6A knockdown cells were plated in triplicate in
er one week, mammospheres were transferred to standard 6-well
. Cells from the primary mammosphere assay were harvested,
00 cells/well. After one week, spheres were processed as above for
of growth. D. Images of secondary mammospheres following two
Table 2. Genes Regulating Growth Identified byGOAnalysis in SUM-52KAT6AKnockdown Cells.
Official Gene Symbol Fold Change P-value
IGF1R −2.42513 0.000109472
ESR1 −2.88771 0.00148708
IRS1 −1.68545 0.00425694
ERBB4 −2.21637 0.00832971
PRKAR2B −1.6321 0.00885831
PRKAR1B −1.50051 0.00958459
WNT9A 1.53544 0.0317711
ADCY7 −1.63293 0.0345432
WNT5A −2.06146 0.0407956
WNT4 −1.77249 0.0467952
DKK1 −1.57585 0.047577
Figure 5. A. Heat map showing gene expression from four replicate
RNA sequencing experiments in SUM-52 KAT6A knockdown and
control cells. A gene list was generated using a 1.5 fold-change
cut-off, 10 reads or more, and P-value of 0.05. A complete list of
genes can be seen in Supplementary Table 1.
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expression (Supplementary Figure 4A and B).
Influence of KAT6A on Gene Expression in SUM-52 Cells
To gain insight into the role of KAT6A as a breast cancer
oncogene, we performed RNA sequencing in SUM-52 KAT6A
knockdown and control cells. The heat map in Figure 5A was
generated from four replicate experiments using the two different
shRNAs described above. Since the replicates from each shRNA
clustered together, we pooled the data resulting in four data sets for
the bioinformatic analysis of the effect of KAT6A knock-down on
gene expression. As can be seen from the figure, KAT6A knockdown
had a significant effect on gene expression. We used NIH DAVID to
analyze the differentially expressed genes that resulted from KAT6ATable 1. Top Biological Processes Identified by GO Analysis of Genes Whose Expression Is
Regulated by KAT6A in SUM-52 Cells.
GO Term Count % P-value
Response to hormone stimulus 19 5.5 2.9E-04
Gland development 11 3.2 2.9E-04
Response to endogenous stimulus 20 5.8 3.5E-04
Response to organic substance 29 8.4 3.6E-04
Epithelium development 14 4.0 4.9E-04
Appendage morphogenesis 9 2.6 6.7E-04
Limb morphogenesis 9 2.6 6.7E-04knockdown, and identified several biological processes, molecular
functions, and KEGG pathways associated with this gene set. The
biological processes affected by KAT6A knockdown are listed in
Table 1, with genes involved in Response to Hormone Stimulus and
Gland Development processes as top hits. From this analysis, several
well-known genes involved in regulating growth were highlighted.
Some of the significantly down-regulated genes in KAT6A
knockdown cells included ESR1, IRS1, IGF1R, and ERBB4
(Table 2 and Supplementary Table 1, 2). Interestingly, not only
was the adenylate cyclase gene ADCY7 significantly down-regulated
in response to KAT6A knockdown, but so were its two regulatory
subunits, PRKAR1B and PRKAR2B. A number of interesting
transcription factors were also identified using NIH DAVID analysis.
As shown in Table 3 (and Supplementary Table 3), GATA3, TBX3,
and MYC were all significantly down-regulated upon KAT6A
knockdown. KEGG pathway analysis yielded additional insight
into the role of KAT6A, showing signaling pathways effected by
knockdown of KAT6A. As seen in Table 5, some of the major
pathways enriched following KAT6A knockdown included Wnt,
PI3K-Akt, Insulin/IGF-1, and ErbB signaling. Finally, merging the
list of significantly regulated genes identified by RNA sequencing in
KAT6A knockdown cells with hits from the genome-wide shRNA
screen in SUM-52 cells identified several overlapping genes, including
IGF1R, IRS1, IGF2BP3, and GATA3 (Table 5). The identification
of genes that are both regulated in expression by KAT6A and hits in
the shRNA screen provides functional evidence for the importance of
these genes and pathways in breast cancer cells with KAT6A
amplification. (See Table 4.)
KAT6A Interacts With FGFR2 to Enhance the Tumorigenicity
of SUM-52 Cells
Previous work from our laboratory identified FGFR2 as a driving
oncogene in SUM-52 cells. We have observed that while FGFR
inhibition can inhibit the growth of these cells, this growth arrest is
reversible, as washout of the drug results in prompt resumption of cell
growth and no significant loss of colony forming ability (unpublishedTable 3. Transcriptional Regulators Identified byGOAnalysis in SUM-52KAT6AKnockdownCells.
Official Gene Symbol Fold Change P-value
BTG2 −1.87652 0.000113777
MYC −1.90468 0.000990004
TBX3 −1.51777 0.00346325
HOXA11 −1.54925 0.0162591
GATA3 −1.70928 0.0319076
HOXB13 −1.51992 0.0471189
Table 4. Top Cancer-Relevant KEGG Pathways in KAT6A SUM-52 Knockdown Cells.
SUM-52
pSize P value FDR
Wnt signaling pathway 143 0.00004 0.001415
PI3K-Akt signaling pathway 347 0.000010 0.002186
Hippo signaling pathway 156 0.000008 0.002186
MAPK signaling pathway 260 0.000086 0.006011
Insulin signaling pathway 140 0.000205 0.006011
Calcium signaling pathway 183 0.000184 0.010928
Hedgehog signaling pathway 51 0.000932 0.011069
ErbB signaling pathway 88 0.000944 0.014924
pSize indicates the number of genes in the KEGG pathway.
P value indicates the probability of obtaining the number of screen hits in the pathway by chance alone.
FDR indicates the global probability corrected for false discovery rate of obtaining the indicated number of
pathway hits by chance alone.
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KAT6A in SUM-52 cells, the colony-forming ability of SUM-52
non-silencing control cells or SUM-52 KAT6A knockdown cells was
examined following treatment with the FGFR inhibitor PD170374. As
shown in Figure 6A, exposure of non-silencing control cells to FGFR
inhibition did not significantly affect the colony-forming ability of
the cells after washout of the drug. As observed previously, the
colony-forming efficiency of SUM-52 KAT6A knockdown cells was
reduced compared to controls. However, unlike the control cells, the
colony-forming efficiency of the KAT6A knockdown cells was
decreased further following 72 hours of exposure to PD173074, and
this decrease was statistically significant (P b .001). Images of colonies
with KAT6A knockdown revealed a striking morphological difference
compared to control colonies. As seen in Figure 6B, non-silencing
control colonies appeared healthy in size and morphology after
treatment and washout of PD170374; however, the KAT6A
knockdown colonies that did grow after drug treatment were much
smaller in size, with cells showing signs of pyknosis. MCF10A cells,
however, were not negatively affected by either KAT6A knockdown or
PD170374 treatment (seen in Figure 6C). These results suggest that the
KAT6A oncogene interacts with the FGFR2 oncogene, a clear driver of
transformed phenotypes in SUM-52 cells, and has an influence on the
response of cells to a targeted receptor tyrosine kinase inhibitor.
Discussion
Elucidation of novel candidate oncogenes from the 8p11-p12
amplicon has been the subject of on-going studies in our laboratory
and a number of other laboratories over many years. The 8p11-p12Table 5. Significantly Regulated Genes Identified by Merging the RNA Sequencing Gene List in
SUM-52 KAT6A Knockdown Cells with Hits from the RNAi Screen Performed in SUM-52 Cells.
Gene Symbol P value Fold Change
KAT6A 1.22264E-05 −1.97641
IGF1R 0.000109472 −2.42513
MTUS1 0.00234984 −1.62862
ANTXR1 0.00258484 −1.82207
CLEC7A 0.00353284 2.66991
IRS1 0.00425694 −1.68545
TUBA1A 0.00804264 −2.51687
DLL3 0.0160265 −1.63383
IGF2BP3 0.0180273 1.85286
UST 0.0222458 −1.55895
MCF2L2 0.0316436 −2.41022
GATA3 0.0319076 −1.70928
TREX1 0.0476831 1.51602amplicon occurs in approximately 15% of breast cancers, the majority
of which are luminal cancers. An interesting feature of this amplicon is
the large number of candidate oncogenes already identified in this the
region, and the consistent finding that many of these genes are
coordinately amplified and overexpressed in breast cancer and lung
cancer [2–4,8,9,12,13,21]. In the present study, we demonstrate that
KAT6A is another candidate oncogene from this region. Gelsi-Boyer et
al. provided compelling evidence that the 8p11-p12 amplicon can be
sub-divided into four distinct regions, each of which can be amplified
independently of the others [3]. We have reported previously on
candidate oncogenes from region III of this amplicon, which contains
genes such as WHSC1L1, DDHD2, and FGFR1[5–7,10,11,22]. The
KAT6A oncogene is in region IV of the amplicon, which is closest to the
centromere. KAT6A is co-amplified with region III oncogenes in
approximately 7%of cases and amplified independently of this region in
approximately 3% of breast cancer cases according to TCGA data.
We found KAT6A to be a consistent hit in an RNAi-based negative
selection screen in SUM-52 breast cancer cells. Since KAT6A is both
amplified and overexpressed in SUM-52 cells, the identification of
KAT6A as a positive screen hit was suggestive of its importance as an
oncogene in this cell line. Validation experiments using several
KAT6A-specific shRNAs confirmed the screen result and demonstrated
a significantly reduced growth rate and reduction in clonogenic potential
in knockdown cells compared to non-silencing controls. Similar results
were obtained using ovarian cancer cell lines that have KAT6A
amplification, but normal mammary epithelial cells, or other breast
cancer cells without the 8p11-p12 amplicon were not affected by
KAT6A knockdown. Analysis of greater than 1000 primary breast
tumors in the TCGA data base showed that KAT6A is amplified in
8.7% of invasive breast cancers, and this amplification is associated with
overexpression at the mRNA level. Furthermore, overexpression of
KAT6A was found to be associated with late recurrence of breast cancer.
Thus, both functional genomics data obtained in our lab and data from
the TCGA point to KAT6A as an important breast cancer oncogene.
Cancer cells are heterogeneous, and within any population of
cancer cells in a cell line, only a relatively small fraction are considered
clonogens based on their ability to form continuously expanding
colonies when grown at clonal density, either in monolayer or in
soft-agar. In the work reported here, we demonstrate a greater than
10-fold decrease in the clonogenic capacity of SUM-52 cells
following knockdown of KAT6A. Colony size distribution shows
that the majority of KAT6A knockdown colonies were smaller
than the non-silencing control colonies. We interpret these results
to indicate that reduction of KAT6A levels not only reduced the
clonogenic fraction of SUM52 cells, but also reduced the growth
rate of colonies that did form from the remaining clonogens.
We were intrigued by the relationship between the dramatic
decrease in colony and mammosphere formation in SUM-52 cells
upon knockdown of KAT6A, and the genes regulated by KAT6A.
IGF1R, IRS1, and ERBB4 were among the genes reduced in
expression as a result of KAT6A knockdown, which is consistent with
a decrease in proliferation and colony formation by these cells.
Interestingly, a recent publication by Heiser et al. showing the efficacy
of 77 compounds in more than 50 breast cancer cell lines showed that
the SUM-52 cell line was among the most sensitive to IGF1R
inhibition [23], a result consistent with our association between
KAT6A overexpression and the IGF1R.
Several interesting transcription factors were also down-regulated
following knockdown of KAT6A, including MYC, TBX3, and
Figure 6. KAT6A interacts with FGFR2 in SUM-52 cells. A. Colony-forming efficiency of SUM-52 control and KAT6A knockdown cells
treated with the FGFR inhibitor PD170374. Cells were treated with 0.1 μM of inhibitor for 3 consecutive days following cell plating, and
colonies were allowed to grow for an additional 10–14 days before staining with 0.2% crystal violet. B. Images of SUM-52 control and
KAT6A knockdown colonies treated with PD170374 taken using an EVOS Imaging System. C. Colony-forming efficiency of MCF10A non-
silencing control and KAT6A knockdown cells treated with PD170374. Colonies were treated and stained as above. D. Histograms
showing colony size distribution for SUM-52 cells treated with PD170374. The histogram on the left represents colonies formed from
untreated cells, and the histogram on the right represents colonies formed from treated cells. E. MCF10A histograms showing colony size
distribution following PD170374 treatment. The histogram on the left represents colonies formed from untreated cells, and the histogram
on the right represents colonies from cells treated with inhibitor.
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occur in leukemia results in an inability of cells to differentiate, which
is in keeping with the known roles of KAT6A and other MYST family
genes in regulation of stem cell self-renewal and differentiation in
hematopoiesis [24–26]. Thus, one mechanism by which KAT6A may
affect breast tumorigenesis is by altering self-renewal capacity and
differentiation of cells of the luminal mammary lineage. Several of our
results are consistent with this hypothesis. Mammosphere formation
in SUM-52 KAT6A knockdown cells was not only significantly
reduced, but so too was the ability of the cells to form large, branching
structures when cultured for extended periods in low-attachment
plates in stem cell medium. The down-regulation of key transcription
factors associated with mammary gland development in KAT6A
knockdown cells is consistent with this observation. C-MYC is a well-known breast cancer oncogene and mechanisms that drive MYC
expression in breast cancer cells play a key role in the growth and
survival of breast cancer cells [27–29]. GATA3 is a key transcription
factor in mammary gland development and plays a role in
determining luminal cell fate [30,31], and as we and others have
shown, KAT6A and other oncogenes of the 8p11 amplicon are over
expressed in luminal breast cancers like the SUM-52 cells. Finally, the
finding of KAT6A regulation of TBX3 provides a link between breast
cancer biology and leukemogenesis induced by this oncogene.
KAT6A regulates expression of TBX1 in hematopoietic progenitor
cells [26], while TBX3 has been shown to play an essential role in
mammary gland development and ductal branching. Furthermore,
TBX3 has been shown to be over expressed in a fraction of breast
cancers, notably estrogen receptor positive, luminal breast cancers
654 KAT6A is a Candidate Oncogene in Luminal Breast Cancer Turner-Ivey et al. Neoplasia Vol. 16, No. 8, 2014[32]. TBX3 has also been found to be an estrogen responsive gene in
MCF-7 cells, and our results show that KAT6A regulates expression
of ESR1 in SUM-52 cells. Thus, the genes regulated by KAT6A in
SUM-52 cells are all key genes in the development of breast cancers of
the luminal lineage, which further implicates KAT6A as a key driver
of luminal breast cancer.
KAT6A, also known as monocytic leukemia zinc finger protein
(MOZ) or MYST3, belongs to the highly conserved MYST family of
histone acetyltransferases, important in post-translational modifica-
tion of histones and chromatin structure. Currently, the MYST
family includes Tip60, MOF, HBO1, MOZ (MYST3), and MORF
[22]. The MYST family is known to acetylate lysine residues on
histones H4, H3, H2A and H2A variants, and recent evidence
suggests that MYST proteins regulate themselves by acetylation.
Specifically, KAT6A has acetyltransferase activity towards lysine
residues on histones H2B, H3 (K14) and H4 (K5, K8, K12, and
K16) [22,26]. Acetylation of histone H3K9 by KAT6A has been
shown in vivo[33]. Although KAT6A is widely-known as an
acetyltransferase, some HAT-independent functions have been
reported. For example, KAT6A interacts with RUNX1 [34,35],
leading to transcription of hematopoietic genes. KAT6A also interacts
with RUNX2 and plays a role in osteogenesis [36,37] and these
functions are independent of HAT activity. KAT6A also interacts
with PU.1, important in the development of lymphoid and myeloid
lineages, and with MLL, a histone methyl transferase that induces
di-and tri-methylation of Histone H3 on lysine 4 [26]. ASH2L,
another amplified and over expressed gene from the 8p11 amplicon has
been shown to be the histone methylase in the MLL complex. The
H3K4 di- and tri-methyl marks are associated with active gene
expression, and KAT6A-MLL interactions have been associated with
expression of homeobox genes in hematopoietic progenitor cells.
Interestingly, two homeobox genes, HOXA11 and HOXA13 were
regulated by KAT6A in SUM-52 cells. Thus, in breast cancer cells with
the 8p11 amplicon, KAT6A may cooperate with other epigenome
modifying oncogenes to aberrantly drive expression of a number of
important cancer genes.
The significance of KAT6A in breast cancer is perhaps best reflected
in the Kaplan-Meier plot shown in Figure 1F, which demonstrates a
significant reduction in overall survival of patients with ER positive
breast cancer and KAT6A amplification and overexpression. Not only is
there a statistically significant divergence in mortality among patients
with KAT6A overexpression, but this affect occurs following
approximately 100 months of survival. This suggests that KAT6A
plays a role in late recurrence of breast cancer, an issue of unique
importance in ER-positive breast cancer. The results reported here
suggest that amplification/overexpression of KAT6A could be a useful
biomarker for predicting the risk of late recurrence, which could aid in
the clinical decisions regarding the duration of anti-estrogen therapy. It
is well-accepted that cancer is a disease driven by genetic abnormalities;
however, it is becoming clear that alterations in epigenetic pathways play
a role in oncogenesis. The identification of KAT6A as a driving
oncogene in breast cancers with 8p11-p12 amplification is consistent
with the emerging field of cancer epigenetics. Future studies will explore
the role of KAT6A in breast cancer self-renewal and mechanisms
governing clonogenicity.While there are other putative oncogenes in the
amplicon, KAT6A has emerged as an oncogene that plays an important
role in the selection of this amplicon in luminal breast cancers.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.07.007.References
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